Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development

Journal of Clinical Oncology

Volumn 23, Issue 34, 2005, Pages 8588-8596

  Knight, Kristin R Gilmer ^a   Kraemer, Dale F ^a   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; FUROSEMIDE; PARACETAMOL; ANTINEOPLASTIC AGENT; PLATINUM DERIVATIVE;

ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; ARTICLE; AUDIOLOGY; AUDIOMETRY; CANCER CHEMOTHERAPY; CHILD; CHILD DEVELOPMENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEARING LOSS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; OTOTOXICITY; PRIORITY JOURNAL; SOCIAL EVOLUTION; SURVIVAL; BONE TUMOR; CEREBELLUM TUMOR; CHEMICALLY INDUCED DISORDER; CHILD WELFARE; COMPARATIVE STUDY; FOLLOW UP; HOSPITALIZATION; INCIDENCE; OTITIS MEDIA; PATHOLOGY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARBOPLATIN; CEREBELLAR NEOPLASMS; CHILD; CHILD WELFARE; CHILD, PRESCHOOL; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS, BILATERAL; HUMANS; INCIDENCE; INFANT; MALE; MEDULLOBLASTOMA; NEUROBLASTOMA; OREGON; OSTEOSARCOMA; OTITIS MEDIA; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644848462     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.00.5355     Document Type: Article

References (34)

1. Blakely BW, Myers SF: Patterns of hearing loss resulting from cisplatinum therapy. Otolaryngol Head Neck Surg 109:385-391, 1993
2. Brock PR, Bellman SC, Yeomans EC, et al: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991
3. Li Y, Womer RB, Silber JH: Predicting ototoxicity in children: Influence of age and the cumulative dose. Eur J Cancer 40:2445-2451, 2004
4. Ilveskoski I, Saarinen DM, Wiklund T, et al: Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol. Med Pediatr Oncol 27:26-31, 1998
5. Montaguti M, Brandolini C, Ferri GG, et al: Cisplatin and carboplatin-induced ototoxicity in children: Clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital 22:14-18, 2002
6. Skinner R, Pearson AD, Amineddine HA, et al: Ototoxicity of cisplatinum in children and adolescents. Br J Cancer 61:927-931, 1990
7. Blair JC, Peterson ME, Viehweg SH: The effects of mild sensorineural hearing loss on academic performance of young school age children. Volta Rev 87:87-93, 1985
8. Doolittle ND, Muldoon LL, Brummett RE, et al: Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500, 2001
9. Dutton SC, Neault M, Billett AE, et al: Progressive ototoxicity after combined modality treatment of medulloblastoma. Proceedings of the 38th annual ASTRO meeting, 2000
10. Parsons SK, Neault MW, Lehmann LE, et al: Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 22:669-674, 1998
11. National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf
12. Campbell KCM, Kelly E, Targovnik N, et al: Audiologic monitoring for potential ototoxicity in a phase I clinical trial of a new glycopeptide antibiotic. J Am Acad Audiol 14:157-169, 2003
13. Ress BD, Sridhar KS, Balkany TJ, et al: Effects of cis-platinum chemotherapy on otoacoustic emissions: The development of an objective screening protocol. Otolaryngol Head Neck Surg 121:693-701, 1999
14. American Speech-Language-Hearing Association: Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 35:11-19, 2004 (suppl 12)
15. Williams PC, Henner WD, Roman-Goldstein S, et al: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37:17-28, 1995
16. Kretschmar CS, Warren MP, Lavally BL, et al: Ototoxicity of pre-radiation cisplatin for children with central nervous system tumors. J Clin Oncol 8:1191-1198, 1990
17. Berg AL, Spitzer JB, Garvin JH: Otologic impact of cisplatin in paediatric oncology patients. Laryngoscope 109:1806-1814, 1999
18. Bertolini P, Lassalle M, Guilaine M, et al: Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. Ped Hematol Oncol 26:649-655, 2004
19. Northern JL, Downs MP: Hearing in Children (ed 4). Baltimore, MD, Williams & Wilkins, 1991
20. Bess FH, Dodd-Murphy J, Parker RA: Children with minimal sensorineural hearing loss: Prevalence, educational performance and functional status. Ear Hear 19:339-354, 1998
21. Boothroyd A: Room acoustics and speech perception, 2002. http://wwwrohan.sdsu.edu/ ~aboothro/files/RoomAcoustics/ Roomacousticsandspeechperception.pdf
22. Stelmachowicz PG, Pittman AL, Hoover BM, et al.: The importance of high frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 103:556-562, 2004
23. Stelmachowicz PG, Pittman A, Hoover B: The effect of stimulus bandwidth on the perception of /s/ in normal and hearing-impaired children and adults. J Acoust Soc Am 110:2183-2190, 2001
24. Horowitz AR, Dubno JR, Ahlstrom JB: Recognition of low-pass-filtered consonants in noise with normal and impaired high frequency hearing. J Acoust Soc Am 111:409-416, 2002
25. French NR, Steinberg JC: Factors governing the intelligibility of speech sounds. J Acoust Soc Am 19:90-119, 1947
26. Eisenberg LS, Shannon RV, Martinez AS, et al: Speech recognition with reduced spectral cues as a function of age. J Acoust Soc Am 107:2704-2710, 2000
27. Katz J, White TP: Introduction to the handicap of hearing impairment: Auditory impairment versus hearing handicap, in Hull R (ed): Aural Rehabilitation (ed 2). San Diego, CA, Singular Publishing Group, 1982, pp 15-27
28. Campbell KCM, Rybak LP, Meech RP: D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 102:90-98, 1996
29. Gandara DR, Weibe VJ, Perez EA, et al: Cisplatin rescue therapy: Experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. Crit Rev Oncol Hematol 10:353-365, 1990
30. Schweitzer VG, Dolan DF, Davidson T, et al: Cisplatin amelioration of ototoxicity by fosfomycin. Laryngoscope 96:948-958, 1986
31. Neuwelt EA, Gilmer-Knight K, Lacy C, et al: Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption. Ped Blood Cancer (in press)
32. Dickey DT, Muldoon LL, Kraemer DF, Neuwelt EA: Protection against ototoxicity by N-acetylcysteine in a rat model. Hear Res 193: 25-30, 2004
33. Dickey DT, Wu J, Muldoon LL, Neuwelt EA: Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular and in vivo levels. J Pharmacol Exp Therapeutics 314:1-7, 2005
34. Neuwelt EA, Pagel MA, Kraemer DF: Bone marrow chemoprotection without compromise of chemotherapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther 309:594-599, 2004